BALAXIBALAXI PHARMACEUTICALS LIMITED
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-15 (delayed ~30 min in market hours)
Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in India, Africa, and Latin America. The company offers pharmaceutical products across various therapeutic areas, including antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpaste. The company was formerly known as Balaxi Ventures Limited and changed its name to Balaxi Pharmaceuticals Limited in October 2020. The company was incorporated in 1942 and is headquartered in Hyderabad, India. Balaxi Pharmaceuticals Limited is a subsidiary of Balaxi Overseas Private Limited.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on BALAXI — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 37/100)
- • Revenue growth: -7.3% YoY
- • Profit growth: -92.9% YoY
- • Price vs EMA21: below
- • Price vs SMA50: below
Bull case
- • Debt/Equity: 0.23
- • MACD: bullish
- • Supertrend: bullish
- • 6-month return: +26.0%
Bear case
- • Revenue growth: -7.3% YoY
- • Profit growth: -92.9% YoY
- • Price vs EMA21: below
- • Price vs SMA50: below
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Revenue growth: -7.3% YoY
- • Profit growth: -92.9% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹1.47). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.